Microsoft Corporation (NASDAQ:MSFT) has released a new video that pictures the imagination of the future technology which holds in the next five to ten years and which includes massive touch screens, Siri-like voice controls, and Microsoft’s Surface tablet.
Earlier, Microsoft has shown the viewers several visions of the future before but this video is quite practical what can actually happen instead of what can be imagined. There are cameos of Windows Phone and Surface as devices that interact with large touch screens and voice commands, because of this Microsoft.
The video was put all together to showcase the opening of Microsoft’s Envisioning Center, which focuses on making improvements to our daily lives with technology.
Microsoft says about the Envisioning Center that the facility includes scenarios at home, at work and places in between which is inspired by Microsoft product teams, Microsoft Research and by the trends across the industry.
Microsoft think it like a concept car that allows to share and experience future technologies with customers to get their feedback, tweak, remix and discuss, which have the best potential. It’s all part of advancing the trends.
As part of today’s market ,if a small video is put together that will give a knowledge of what’s inside and while none of the ideas can be predicted for the products. Some of the key trends which are getting invested such as machine learning and NUI are been highlighted.
They will acknowledge where these technologies could lead ones over the next five to ten years.
Big Movers: Merrimack Pharmaceuticals Inc(NASDAQ:MACK), Keryx Biopharmaceuticals (NASDAQ:KERX), Array Biopharma Inc (NASDAQ:ARRY)
Lakeway, NY — (MARKET NEWS CALL) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Array Biopharma Inc (NASDAQ:ARRY), Merrimack Pharmaceuticals Inc(NASDAQ:MACK), Keryx Biopharmaceuticals (NASDAQ:KERX).
Array Biopharma Inc (NASDAQ:ARRY)’s shares decreased 0.86% to $4.59. The company on Dec. 3 announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties.
Merrimack Pharmaceuticals Inc(NASDAQ:MACK)’s shares gained 2.02% to $10.08. The company on Dec. 12 announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in San Antonio, TX. Presentations include preclinical research and clinical data on MM-398, MM-302 and MM-121.
Presentations on Merrimack’s nanoliposomal platform include an abstract detailing clinical data from a cohort of ER/PR-positive metastatic breast patients treated with MM-398, a nanoliposomal encapsulation of irinotecan, in a cross-indication translational study investigating potential predictive response markers for MM-398 therapy.
Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares fell 1.17% to $13.57. The company on Dec. 4 announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2, 2014. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate having a BET active surface area greater than about 16 sq. m/g. The patent also claims a broad category of orally administrable forms covering Auryxia, as well as other oral formulations that could be developed in the future.
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.
Traders Favroite: Advanced Micro Devices, Inc. (NYSE:AMD), DryShips, Inc. (NASDAQ:DRYS), Plug Power Inc. (NASDAQ:PLUG)
Lakeway, NY — (US MARKET BUZZ) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Advanced Micro Devices, Inc. (NYSE:AMD), DryShips, Inc. (NASDAQ:DRYS), Plug Power Inc. (NASDAQ:PLUG).
Advanced Micro Devices, Inc. (NYSE:AMD)’s shares fell 0.81% to $2.46. The company announced that President and CEO Dr. Lisa Su will present at the J.P. Morgan 13th Annual Tech Forum at International CES on Tuesday, January 6, 2015 at 2:25 p.m. PST in Las Vegas.
Additionally, the company on Dec. 15 announced James A. Clifford (69) has joined the company as senior vice president of Global Operations, reporting to President and CEO Dr. Lisa Su. Clifford will be responsible for overseeing all aspects of AMD’s end-to-end manufacturing and supply chain strategy.
DryShips, Inc. (NASDAQ:DRYS)’s shares decreased 1.35% to $0.80. The company on Dec. 1 announced that it has repaid all remaining principal and interest of its 5% Convertible Notes due 2014, in accordance with the terms of the notes and the indenture governing the notes.
Additionally, the company on Dec. 1 also announced that its 2014 Annual General Meeting of Shareholders, scheduled for, and convened on December 1, 2014, was adjourned due to lack of requisite quorum. The Company has set a new record date of Nov. 4, 2014 and only shareholders as of Nov. 4, 2014 are entitled to and are being requested to vote at the Meeting in person or by proxy.
Plug Power Inc. (NASDAQ:PLUG)’s shares declined 1.44% to $2.73. The company on Dec. 16 announced that it has been named to the 2014 Food Logistics FL100+ list. Food Logistics is the only publication dedicated exclusively to the global food and beverage supply chain. The publication’s 11th annual FL100+ list profiles innovative technology and software providers who influence the global food and beverage supply chains.
Additionally, the company on Dec. 4 announced that it has executed a multi-year contract for its ReliOn integrated fuel cell solution and GenFuel hydrogen services to be used with a major North American telecommunications provider.
Special News: VIVUS, Inc. (NASDAQ:VVUS), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Idenix Pharmaceuticals Inc (NASDAQ:IDIX)
VIVUS, Inc. (NASDAQ:VVUS)’s shares jumped 0.62% to $4.86. The company on June 12 announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.
The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Qsymia® (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents 7,056,890, 7,553,818, 7,659,256, 7,674,776, 8,580,298, and 8,580,299, which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. VIVUS filed the lawsuit on the basis that Actavis’s proposed generic products infringe each of these patents held by VIVUS.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares decreased 0.23% to $4.40. The 52 week trading range for the company is $3.70 – $7.85. The company is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development.
Idenix Pharmaceuticals Inc (NASDAQ:IDIX)’s shares gained 0.84% to $24.06. The securities litigation law firm of Brower Piven, A Professional Corporation, on June 16 has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals, Inc. (IDIX) and other violations of state law by the board of directors of Merck & Co., Inc. (“Merck”), in a transaction valued at approximately $3.85 billion. Under the terms of the transaction, shareholders of Idenix would receive $24.50 in cash for each share of Idenix they own.